Cognitive impairment in schizophrenia

Handbook of Experimental Pharmacology

Volumn 213, Issue , 2012, Pages 11-37

  Keefe, Richard S E ^a   Harvey, Philip D ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Attention; Cognition; Cognitive neuroscience; Cognitive remediation; Enhancement; Executive functioning; Memory; Neurocognition; Neuropsychology; Processing speed; Social cognition

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADD ON THERAPY; ALERTNESS; ARTICLE; ATTENTION DISTURBANCE; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COGNITIVE REMEDIATION; COMORBIDITY; CONSENSUS DEVELOPMENT; DAILY LIFE ACTIVITY; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; JOB PERFORMANCE; LEARNING DISORDER; MEMORY DISORDER; MENTAL FUNCTION; MOTIVATION; NEGATIVE SYNDROME; NEUROBIOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SCHIZOPHRENIA; SOCIAL DISABILITY; SOCIAL INTERACTION; SOCIOECONOMICS; TREATMENT DURATION; VISUAL INFORMATION; WORKING MEMORY; ATTENTION; LEARNING; MEMORY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; REVIEW;

ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION DISORDERS; HUMANS; LEARNING; MEMORY; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84868328942     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25758-2_2     Document Type: Article

References (133)

1. Addington J, Addington D (1998) Facial affect recognition and information processing in schizophrenia and bipolar disorder. Schizophr Res 32:171-181 (Pubitemid 28383775)
2. Addington J, Addington D (2000) Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res 44:47-56 (Pubitemid 30365206)
3. Addington J, Addington D, Maticka-Tyndale E (1991) Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr Res 5:123-134
4. Aleman A, Hijman R, de Haan EH, Kahn RS (1999) Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358-1366 (Pubitemid 29416531)
5. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders DSM-IV-TR, Text Revision 4th edn. American Psychiatric Association, Washington, DC, ISBN 0-89042-024-6
6. Baddeley A (1992) Working memory. Science 255:556-559, Review
7. Barch DM, Keefe RSE (2010) Anticipating DSM-V: Opportunities and challenges for cognition and psychosis. Schizophr Bull 36:43-47
8. Bell MD, Bryson G (2001) Work rehabilitation in schizophrenia: does cognitive impairment limit improvement? Schizophr Bull 27:269-279 (Pubitemid 33644302)
9. Bell MD, Greig TC, Kaplan E, Bryson G (1997) Wisconsin Card Sorting Test dimensions in schizophrenia: factorial, predictive, and divergent validity. J Clin Exp Neuropsychol 19:933-941 (Pubitemid 28153422)
10. Bilder RM, Mukherjee S, Rieder RO, Pandurangi AK (1985) Symptomatic and neuropsychological components of defect states. Schizophr Bull 11:409-419 (Pubitemid 15036184)
11. Brekke JS, Long JD, Nesbitt N, Sobel E (1997) The impact of service characteristics on functional outcomes from community support programs for persons with schizophrenia: a growth curve analysis. J Consult Clin Psychol 65:464-475 (Pubitemid 27246788)
12. Brekke JS, Kohrt B, Green MF (2001) Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull 27:697-708 (Pubitemid 34093255)
13. Brekke JS, Hoe M, Long J, Green MF (2007) How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull 33:1247-1256 (Pubitemid 47347914)
14. Bressi S, Miele L, Bressi C et al (1996) Deficit of central executive component of working memory in schizophrenia. New Trends Exp Clin Psychiatry 12:243-252 (Pubitemid 27173665)
15. Brewer WJ, Wood SJ, McGorry PD, Francey SM, Phillips LJ, Yung AR, Anderson V, Copolov DL, Singh B, Velakoulis D, Pantelis C (2003) Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am J Psychiatry 160:1790-1794 (Pubitemid 41103312)
16. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD (2005) Memory impairments identified in people at ultra-high risk for psychosis who later develop first episode psychosis. Am J Psychiatry 162:71-78 (Pubitemid 40095675)
17. Buchanan RW, Holstein C, Breier A (1994) The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36:717-725 (Pubitemid 24365878)
18. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levine R, Stover E, Fenton W, Marder SR (2005) A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31:5-19 (Pubitemid 41214353)
19. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR (2011a) The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: What do we know 5 years later? Schizophr Bull 37:1209-1017
20. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR (2011b) A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 69:442-449
21. Burdick KE, Goldberg TE, Cornblatt BA, Keefe RS, Gopin CB, Derosse P, Braga RJ, Malhotra AK (2011) The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology 36:1587-1592
22. Callicott JH, Mattay VS, Bertolino A, Finn K, Coppola R, Frank JA, Goldberg TE, Weinberger DR (1999) Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex 9:20-26 (Pubitemid 29062016)
23. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, WalkerE, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R (2008) Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65:28-37
24. Carter CS, Barch DM (2007) Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 33:1131-1137 (Pubitemid 47347921)
25. Carter C, Robertson L, Nordahl T, Chaderjian M, Kraft L, O'Shora-Celaya L (1996) Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients. Biol Psychiatry 40:930-932 (Pubitemid 26356731)
26. Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R (2008) Identifying cognitive mechanisms targeted for treatment development in schizophrenia: An overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry 64:4-10
27. Caspi A, Reichenberg A, Weiser M, Rabinowitz J, Kaplan Z, Knobler H, Davidson-Sagi N, Davidson M (2003) Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr Res 65:87-94 (Pubitemid 37434015)
28. Corcoran R, Mercer G, Frith CD (1995) Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia. Schizophr Res 17:5-13
29. Corrigan PW, Liberman RP, Engel JD (1990) From noncompliance to collaboration in the treatment of schizophrenia. Hosp Commun Psychiatry 41:1203-1211 (Pubitemid 20368357)
30. David AS, Malmberg A, Brandt L, Allebeck P, Lewis G (1997) IQ and risk for schizophrenia: A population-based cohort study. Psychol Med 27:1311-1323 (Pubitemid 27494097)
31. Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RS, Frecska E (1995) Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 152:197-207
32. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M (1999) Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry 156:1328-1335 (Pubitemid 29416527)
33. Davis SM, Koch GG, Davis CE, LaVange LM (2003) Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies. Schizophr Bull 29:73-80 (Pubitemid 36871058)
34. Dias EC, Butler PD, Hoptman MJ, Javitt DC (2011) Early sensory contributions to contextual encoding deficits in schizophrenia. Arch Gen Psychiatry 68:654-664
35. Dickerson F, Boronow JJ, Ringel N, Parente F (1999) Social functioning and neurocognitive deficits in outpatients with schizophrenia: A 2-year follow-up. Schizophr Res 37:13-20 (Pubitemid 29167022)
36. Dickinson D, Ramsey ME, Gold JM (2007) Overlooking the obvious: A meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 64:532-542 (Pubitemid 46718286)
37. Donohoe G, Owens N, O'Donnell C, Burke T, Moore L, Tobin A, O'Callaghan E (2001) Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: A discriminant function analysis. Eur Psychiatry 16:293-298 (Pubitemid 32743588)
38. Drury VM, Robinson EJ, Birchwood M (1998) Theory of mind skills during an acute episode of psychosis and following recovery. Psychol Med 28:1101-1112 (Pubitemid 28458466)
39. Edwards J, Pattison PE, Jackson HJ, Wales RJ (2001) Facial affect and affective prosody recognition in first-episode schizophrenia. Schizophr Res 48:235-253 (Pubitemid 32274319)
40. Ertuǧrul A, Uluǧ B (2002) The influence of neurocognitive deficits and symptoms on disability in schizophrenia. Acta Psychiatr Scand 105:196-201 (Pubitemid 34280692)
41. Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, Jeste DV (2003) The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenic patients. Biol Psychiatry 53:422-430 (Pubitemid 36263016)
42. Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23:637-651 (Pubitemid 27485972)
43. Friedman L (2002) Psychoanalysis: practice and technique. J Am Psychoanal Assoc 50:727-732
44. Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC (2002) Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 159:1183-1189 (Pubitemid 34743259)
45. Gaebel W, Wölwer W (1992) Facial expression and emotional face recognition in schizophrenia and depression. Eur Arch Psychiatry Clin Neurosci 242:46-52
46. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR (2000) Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157:1835-1842
47. Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF (2002) Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 159:1395-1402 (Pubitemid 34832723)
48. Gold JM, Wilk CM, McMahon RP, Buchanan RW, Luck SJ (2003) Working memory for visual features and conjunctions in schizophrenia. J Abnorm Psychol 112:61-71 (Pubitemid 36249844)
49. Goldberg TE, Weinberger DR, Berman KF, Pliskin NH, Podd MH (1987) Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Arch Gen Psychiatry 44:1008-1014 (Pubitemid 18009657)
50. Goldberg TE, Ragland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR (1990) Neuropsy-chological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 47:1066-1072 (Pubitemid 20377518)
51. Goldman-Rakic PS (1987) Circuitry of the frontal association cortex and its relevance to dementia. Arch Gerontol Geriatr 6:299-309 (Pubitemid 17140261)
52. Goldman-Rakic PS (1994) Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 6:348-357 (Pubitemid 24344855)
53. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321-330 (Pubitemid 26074706)
54. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26:119-136, Review (Pubitemid 30317696)
55. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RSE, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301-307 (Pubitemid 39164514)
56. Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR (2011) Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry 168:400-407
57. Harvey PD, Keefe RSE (1997) Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums 2:1-11
58. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M (2005) Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 162:1888-1895 (Pubitemid 41428618)
59. Harvey PD, Velligan DI, Bellack AS (2007) Performance-based measures of functional skills: usefulness in clinical treatment studies. Schizophr Bull 33:1138-1148 (Pubitemid 47347915)
60. Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipursky R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH (2004) Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res 67:115-122 (Pubitemid 38251441)
61. Heaton RK, Pendleton MG (1981) Use of Neuropsychological tests to predict adult patients' everyday functioning. J Consult Clin Psychol 49:807-821 (Pubitemid 12028262)
62. Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12:426-445 (Pubitemid 28323862)
63. Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299:350-351
64. Jarboe KS, Schwartz SK (1999) The relationship between medication noncompliance and cognitive function in patients with schizophrenia. J Am Psychiatr Nurses Assoc 5:S2-S8
65. Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, Jeste DV (2003) Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res 63:49-58 (Pubitemid 36929845)
66. Jones P, Rodgers B, Murray R, Marmot M (1994) Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344:1398-1402 (Pubitemid 24365314)
67. Keefe RSE (1995) The contribution of neuropsychology to psychiatry. Am J Psychiatry 152:6-15
68. Keefe RSE (2000) Working memory dysfunction and its relevance in schizophrenia. In: Sharma T, Harvey PD (eds) Cognition in schizophrenia: characteristics, correlates, and treatment. Oxford University Press, Oxford, pp 16-49
69. Keefe RSE, Fenton WS (2007) How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 33:912-920 (Pubitemid 47216649)
70. Keefe RSE, Harvey PD (2008) Implementation considerations for multi-site clinical trials with cognitive neuroscience tasks. Schizophr Bull 34:656-663 (Pubitemid 351957563)
71. Keefe RSE, Kraus MS (2009) Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. Ann Acad Med Sing 38:414-416
72. Keefe RSE, Arnold MC, Bayen UJ, McEvoy JP, Wilson WH (2002) Source monitoring deficits for self-generated stimuli in schizophrenia: Multinomial modeling of data from three sources. Schizophr Res 57:51-67
73. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized double-blind trial of olanzapine versus low-doses of haloperidol. Am J Psychiatry 161:985-99
74. Keefe RSE, Eesley CE, Poe M (2005) Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 57:688-691 (Pubitemid 40409709)
75. Keefe RSE, Bilder RM, Harvey PD, Sm D, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA (2006a) Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31:2033-2046
76. Keefe RSE, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA (2006b) A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr Res 88:26-35 (Pubitemid 44693238)
77. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hasiao JK, Lieberman JA, CATIE Investigators, Neurocognitive Working Group (2007a) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64:633-647 (Pubitemid 46878665)
78. Keefe RSE, Malhotra AK, Meltzer H, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R (2007b) Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33:1217-1228
79. Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A (2011a) Characteristics of the MATRICS consensus cognitive battery in a 29 site antipsychotic schizophrenia clinical trial. Schizophr Res 125:161-168
80. Keefe RSE, Kraus MS, Krishnan RR (2011b) Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia. Neuropsychopharmacology 36:367-380
81. Keefe R, Buchanan R, Marder S et al (2011c) Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far? Annual Meeting of NCDEU, Boca Raton, FL
82. Keefe RSE, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS (2011d) Report from the Working Group Conference on multi-site trial design for cognitive remediation in schizophrenia. Schizophr Bull 37:1057-1065
83. Keefe RSE, Vinogradov S, Medalia A, Buckley PF, Caroff SN, d'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, Haim AJ, Stroup TS (2012) Feasibility and pilot efficacy results from the multi-site Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) study. J Clin Psychiatry 73: 1016-1022
84. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR (2008) The MATRICS consensus cognitive battery: Part 2. Co-norming and standardization. Am J Psychiatry 165:214-220 (Pubitemid 351704521)
85. Kraemer HC, Frank E (2010) Evaluation of comparative treatment trials: assessing clinical benefits and risks for patients, rather than statistical effects on measures. J Am Med Assoc 304:683-684
86. Kraus MS, Keefe RSE, Krishnan RK (2009) Memory-prediction errors and their consequences in schizophrenia. Neuropsychol Rev 19:336-352
87. Kremen WS, Seidman LJ, Faraone SV, Toomey R, Tsuang MT (2000) The paradox of normal neuropsychological function in schizophrenia. J Abnorm Psychol 109:743-752 (Pubitemid 32096236)
88. Krishnan RR, Fivaz M, Kraus M, Keefe RSE (2011a) Hierarchical temporal processing deficit model of reality distortion and psychoses. Mol Psychiatry 16:129-144
89. Krishnan RR, Kraus MS, Keefe RSE (2011b) Comprehensive model of how reality distortion and symptoms occur in schizophrenia. Could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia? Psychiatry Clin Neurosci 65:305-317
90. Leung WW, Bowi CR, Harvey PD (2008) Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study. J Int Neuropsychol Soc 14:479-488 (Pubitemid 351560443)
91. Lysaker P, Bell M (1995) Work rehabilitation and improvements in insight in schizophrenia. J Nerv Ment Dis 183:103-106
92. Malla AK, Norman RM, Manchanda R, Townsend L (2002) Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 32:1109-1119
93. Mausbach BT, Bowie CR, Harvey PD, Twamley EW, Goldman SR, Jeste DV, Patterson TL (2008) Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J Psychiatr Res 42:320-327 (Pubitemid 351199854)
94. McClure MM, Bowie CR, Patterson TL, Heaton RK, Weaver C, Anderson H, Harvey PD (2007) Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships? Schizophr Res 89:330-338 (Pubitemid 44881282)
95. McGurk SR, Meltzer HY (2000) The role of cognition in vocational functioning in schizophrenia. Schizophr Res 45:175-184
96. McGurk SR, Mueser KT, Harvey PD, LaPuglia R, Marder J (2003) Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatr Serv 54:1129-1135 (Pubitemid 36951514)
97. McGurk SR, Mueser KT, Feldman K, Wolfe R, Pascaris A (2007a) Cognitive training for supported employment: 2-3 year outcomes of a randomized controlled trial. Am J Psychiatry 164:437-441 (Pubitemid 46513157)
98. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT (2007b) A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 164:1791-1802 (Pubitemid 351739231)
99. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N (1999) Generalized cognitive deficits in schizophrenia: A study of first-episode patients. Arch Gen Psychiatry 56:749-754 (Pubitemid 29357737)
100. Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS (2008) Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 165:978-987
101. Morrison RL, Bellack AS, Mueser KT (1988) Deficits in facial-affect recognition and schizophrenia. Schizophr Bull 14:67-83, Review
102. Mueser KT, Bellack AS, Douglas MS, Wade JH (1991) Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology. Psychiatry Res 37:281-296
103. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004) Identification of separable cognitive factors in schizophrenia. Schizophr Res 72:29-39, Review (Pubitemid 39452903)
104. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ III, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008) The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165:203-213 (Pubitemid 351704520)
105. Palmer BW, Heaton RK, Paulsen JS, Kuck J, Braff D, Harris MJ, Zisook S, Jeste DV (1997) Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 11:437-446 (Pubitemid 27294667)
106. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV (2001) UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull 27:235-245 (Pubitemid 33644299)
107. Patterson TL, Lacro J, McKibbin CL, Moscona S, Hughs T, Jeste DV (2002) Medication management ability assessment: results from a performance-based measure in older outpatients with schizophrenia. J Clin Psychopharmacol 22:11-19 (Pubitemid 34101287)
108. Penn DL, Spaulding W, Reed D, Sullivan M (1996) The relationship of social cognition to ward behavior in chronic schizophrenia. Schizophr Res 20:327-335 (Pubitemid 26232978)
109. Penn DL, Corrigan PW, Bentall RP, Racenstein JM, Newman L (1997) Social cognition in schizophrenia. Psychol Bull 121:114-132 (Pubitemid 127705287)
110. Pinkham AE, Loughead J, Ruparel K, Overton E, Gur RE, Gur RC (2011) Abnormal modulation of amygdala activity in schizophrenia in response to direct- and averted-gaze threat-related facial expressions. Am J Psychiatry 168:293-301
111. Reichenberg A, Harvey PD, Bowie CR, Mojtabai R, Rabinowitz J, Heaton RK, Bromet E (2009) Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull 35:1022-1029
112. Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, Poulton R, Moffitt TE (2010) Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: A 30-year study. Am J Psychiatry 167:160-169
113. Reilly JL, Harris MSH, Keshavan MS, Sweeney JA (2006) Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry 63:1189-1197 (Pubitemid 44708076)
114. Rosenheck R, Doyle J, Leslie D, Fontana A (2003) Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs. Schizophr Bull 29:81-93 (Pubitemid 36871059)
115. Sarfati Y, Hardy-Bayle MC, Nadel J et al (1997) Attribution of mental states to others by schizophrenic patients. Cogn Neuropsychiatr 2:1-17 (Pubitemid 127700330)
116. Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P (1991) Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 48:618-624
117. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA, North American Prodrome Longitudinal Study (NAPLS) Group (2010) Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 67:578-588
118. Sevy S, Davidson M (1995) The cost of cognitive impairment in schizophrenia. Schizophr Res 17:1-3
119. Silver H, Feldman P, Bilker W, Gur RC (2003) Working memory deficit as a core neuropsycho-logical dysfunction in schizophrenia. Am J Psychiatry 160:1809-1816 (Pubitemid 41103315)
120. Strauss ME (1993) Relations of symptoms to cognitive deficits in schizophrenia. Schizophr Bull 19:215-231, Review (Pubitemid 23183146)
121. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, Investigators CATIE (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia after discontinuing a previous atypical antipsychotic. Am J Psychiatry 13:611-622 (Pubitemid 44464570)
122. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC (2003) Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull 29:33-43 (Pubitemid 36871055)
123. Sweet RA, Pollock BG, Mulsant BH, Rosen J, Sorisio D, Kirshner M, Henteleff R, DeMichele MA (2000) Pharmacologic Profile of Perphenazine's Metabolites. J Clin Psychopharmacol 20:181-187 (Pubitemid 30202360)
124. Tamlyn D, McKenna PJ, Mortimer AM, Lund CE, Hammond S, Baddeley AD (1992) Memory impairment in schizophrenia: Its extent, affiliations and neuropsychological character. Psychol Med 22:101-115
125. Tan HY, Choo WC, Fones CS, Chee MW (2005) fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. Am J Psychiatry 162:1849-1858 (Pubitemid 41428614)
126. Trumbetta SL, Mueser KT (2001) Social functioning and its relationship to cognitive deficits over the course of schizophrenia. In: Keefe RSE, McEvoy JP (eds) Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia. American Psychiatric Association, Washington, DC, pp 33-67
127. Twamley EW, Doshi RR, Nayak GV, Palmer BW, Golshan S, Heaton RK, Patterson TL, Jeste DV (2003) Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am J Psychiatry 159:2013-2020 (Pubitemid 35423859)
128. Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N (1991) Neuroleptic plasma levels. Schizophr Bull 17:197-216
129. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC (2000) Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 188:518-524 (Pubitemid 30641896)
130. Walker E, Lewine RJ (1988) The positive/negative symptom distinction in schizophrenia. Validity and etiological relevance. Schizophr Res 1:315-328
131. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669 (Pubitemid 17099795)
132. Wykes T, Reeder C, Corner J, Williams C, Everitt B (1999) The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophr Bull 25:291-307 (Pubitemid 29272506)
133. Yung AR, McGorry PD (1996) The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 22:353-370 (Pubitemid 26174579)